RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nykode Therapeutics A Stock

Nykode Therapeutics A Stocks 2024

Nykode Therapeutics A Stocks

300.52 M

Ticker

NYKD.OL

ISIN

NO0010714785

WKN

A2PZ5J

In 2024, Nykode Therapeutics A had 300.52 M outstanding stocks, a 0% change from the 300.52 M stocks in the previous year.

The Nykode Therapeutics A Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e300.52
2028e300.52
2027e300.52
2026e300.52
2025e300.52
2024e300.52
2023300.52
2022290.12
2021286.34
2020296.15
201954.97
201855.8
201755.8
201655.8

Nykode Therapeutics A shares outstanding

The number of shares was Nykode Therapeutics A in 2023 — This indicates how many shares 300.52 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nykode Therapeutics A earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nykode Therapeutics A's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nykode Therapeutics A’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nykode Therapeutics A's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nykode Therapeutics A Aktienanalyse

What does Nykode Therapeutics A do?

Vaccibody AS is a Norwegian biotechnology company that was founded in 2007. It is headquartered in Oslo and currently employs about 40 people. The company specializes in the development of individualized vaccines based on DNA-based technology. The idea for founding Vaccibody came about when the two founders, Agnete Fredriksen and Bjarne Bogen, were collaborating at the University of Oslo. They wanted to develop a method to personalize vaccines in order to increase their effectiveness and compatibility. Their discovery is based on the fact that T-cells play an important role in the immune system and can recognize specific target proteins produced by cancer cells or viruses. Vaccibody's business model is based on the development of individualized vaccines based on DNA-based technology. The company has several different areas, including cancer immunotherapy, infectious diseases, and personalized medicine. Vaccibody's vaccines can be used for various types of cancer, such as lung, breast, and prostate cancer. Vaccibody offers a range of products, including a vaccine against HPV (human papillomavirus) that is approved for women aged 9 to 45. This vaccine aims to reduce the risk of cervical cancer. Another product from Vaccibody is the prostate cancer vaccine VCD-001. This vaccine uses the antigen PSA (prostate-specific antigen), which occurs on the surface of prostate cancer cells, to stimulate the patient's immune system. Vaccibody is also working on the development of vaccines against COVID-19 and has already achieved initial positive results in preclinical studies. As part of its personalized medicine division, Vaccibody offers the DNA platform VACCIBODY®, which is used to manufacture individualized DNA vaccines. This technology allows the vaccine to be tailored specifically to the needs of each patient. Vaccibody has achieved many important milestones since its inception. In 2018, the company received a $12.5 million investment to further develop its cancer immunotherapy platform. In 2020, Vaccibody received an additional $43.5 million investment to advance the development of its COVID-19 vaccine. Overall, Vaccibody has the potential to change the way vaccines are developed and used. DNA-based technology offers many advantages over conventional vaccines, especially in personalized medicine. Vaccibody is working hard to further develop its technology and bring its products to market in order to improve the lives of people around the world. Nykode Therapeutics A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Nykode Therapeutics A's Shares Outstanding

Nykode Therapeutics A's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Nykode Therapeutics A’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Nykode Therapeutics A’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Nykode Therapeutics A’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Nykode Therapeutics A stock

How many stocks are there of Nykode Therapeutics A?

The current number of stocks of Nykode Therapeutics A is 300.52 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Nykode Therapeutics A are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Nykode Therapeutics A evolved in recent years?

The number of shares of Nykode Therapeutics A has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Nykode Therapeutics A as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Nykode Therapeutics A?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Nykode Therapeutics A pay?

Over the past 12 months, Nykode Therapeutics A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nykode Therapeutics A is expected to pay a dividend of 0 USD.

What is the dividend yield of Nykode Therapeutics A?

The current dividend yield of Nykode Therapeutics A is .

When does Nykode Therapeutics A pay dividends?

Nykode Therapeutics A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nykode Therapeutics A?

Nykode Therapeutics A paid dividends every year for the past 0 years.

What is the dividend of Nykode Therapeutics A?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nykode Therapeutics A located?

Nykode Therapeutics A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nykode Therapeutics A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nykode Therapeutics A from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Nykode Therapeutics A pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Nykode Therapeutics A in the year 2023?

In the year 2023, Nykode Therapeutics A distributed 0 USD as dividends.

In which currency does Nykode Therapeutics A pay out the dividend?

The dividends of Nykode Therapeutics A are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nykode Therapeutics A

Our stock analysis for Nykode Therapeutics A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nykode Therapeutics A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.